Fierce Biotech May 28, 2024
Gilead Sciences is drawing up $20 million cash to partner with Cartography Biosciences and navigate drug discovery for triple-negative breast cancer and adenocarcinoma, a common form of non-small cell lung cancer.
The multiyear partnership will use Cartography’s computational and genomics platform in efforts to discover novel tumor-selective target antigens and pairs of antigens. Gilead can then opt in on several targets identified through the deal, taking over responsibility for all further research, development and commercialization of the selected programs.
In turn, Cartography will receive $20 million upfront and earn more near-term preclinical milestones as well. The biotech is also eligible to receive an undisclosed amount of development, regulatory and commercial milestones,...
Today's Sponsors
Today's Sponsor